Coave has raised €32m ($33m) in a Series A financing round for advancing its Advanced Vectors-Ligand Conjugates (ALIGATER) platform.

Challenge trials help researchers study immune responses. Skeptics still doubt the approach is worth the risks ...

It's one of many steps for the company as it builds the infrastructure for what "will change medicine everywhere in the world ...